- Home
- CVRX vs GNLX Comparison
CVRX vs GNLX Comparison
Compare CVRX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVRX | GNLX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.0M | 202.4M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CVRX | GNLX |
|---|---|---|
| Price | $7.31 | $2.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $13.17 | ★ $19.75 |
| AVG Volume (30 Days) | 371.4K | ★ 377.8K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $55,969,000.00 | N/A |
| Revenue This Year | $11.91 | N/A |
| Revenue Next Year | $15.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.44 | N/A |
| 52 Week Low | $4.30 | $1.99 |
| 52 Week High | $17.78 | $8.54 |
Technical Indicators
Market Signals| Indicator | CVRX | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 34.53 |
| Support Level | $6.96 | $2.75 |
| Resistance Level | $6.09 | $2.97 |
| Average True Range (ATR) | 0.81 | 0.19 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 60.17 | 56.80 |
Price Performance
Historical ComparisonAbout CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.